^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | rintodestrant (G1T48) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection
Published date:
11/17/2020
Excerpt:
...rintodestrant monotherapy in women with ER+/HER2- ABC…Of 67 patients, 16 were on study treatment for ≥24 weeks and 3 (n = 1 at 600 mg; n = 2 at 1000 mg, including 1 with ESR1 mutation) had a confirmed partial response (clinical benefit rate [CBR]: 28%).
Trial ID:
